IL325213A - The compositions and methods for modulating tau expression - Google Patents

The compositions and methods for modulating tau expression

Info

Publication number
IL325213A
IL325213A IL325213A IL32521325A IL325213A IL 325213 A IL325213 A IL 325213A IL 325213 A IL325213 A IL 325213A IL 32521325 A IL32521325 A IL 32521325A IL 325213 A IL325213 A IL 325213A
Authority
IL
Israel
Prior art keywords
compositions
methods
tau expression
modulating tau
modulating
Prior art date
Application number
IL325213A
Other languages
English (en)
Hebrew (he)
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of IL325213A publication Critical patent/IL325213A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL325213A 2023-06-22 2025-12-08 The compositions and methods for modulating tau expression IL325213A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363509696P 2023-06-22 2023-06-22
PCT/US2024/034923 WO2024263852A2 (en) 2023-06-22 2024-06-21 Compositions and methods for modulating tau expression

Publications (1)

Publication Number Publication Date
IL325213A true IL325213A (en) 2026-02-01

Family

ID=93936381

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325213A IL325213A (en) 2023-06-22 2025-12-08 The compositions and methods for modulating tau expression

Country Status (7)

Country Link
EP (1) EP4731767A2 (de)
KR (1) KR20260026011A (de)
CN (1) CN121729493A (de)
AU (1) AU2024313057A1 (de)
IL (1) IL325213A (de)
MX (1) MX2025015410A (de)
WO (1) WO2024263852A2 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020018365A2 (pt) * 2018-03-13 2020-12-29 Janssen Pharmaceutica Nv Oligonucleotídeos modificados e métodos para uso em tauopatias
MX2024003519A (es) * 2021-09-24 2024-04-01 Alnylam Pharmaceuticals Inc Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
KR20250031159A (ko) * 2022-07-01 2025-03-06 데날리 테라퓨틱스 인크. 세포에 올리고뉴클레오타이드를 전달하기 위한 트랜스페린 수용체 결합 분자 접합체

Also Published As

Publication number Publication date
CN121729493A (zh) 2026-03-24
EP4731767A2 (de) 2026-04-29
AU2024313057A1 (en) 2025-10-30
WO2024263852A2 (en) 2024-12-26
KR20260026011A (ko) 2026-02-25
MX2025015410A (es) 2026-02-03
WO2024263852A3 (en) 2025-05-15

Similar Documents

Publication Publication Date Title
EP3920918A4 (de) Verfahren und zusammensetzungen zur modulierung von spleissung
IL287398A (en) Methods and preparations for modulating composition and translation
IL290595A (en) Compositions and methods for modulating protein fusion and expression
EP3920915A4 (de) Verfahren und zusammensetzungen zur modulierung der spleissung
EP3920919A4 (de) Verfahren und zusammensetzungen zur modulierung der spleissung
EP3920916A4 (de) Verfahren und zusammensetzungen zur modulierung der spleissung
EP3920920A4 (de) Verfahren und zusammensetzungen zur modulierung von spleissung
EP4125434A4 (de) Zusammensetzungen und verfahren zur modulation der entzündungsreaktion
EP3921311A4 (de) Verfahren und zusammensetzungen zur spleissungsmodulierung
EP3938352A4 (de) Verfahren und zusammensetzungen zur spleissungsmodulierung
EP3920910A4 (de) Verfahren und zusammensetzungen zur modulierung der spleissung
EP4127172A4 (de) Verfahren und zusammensetzungen zur wiederherstellung des stmn2-spiegels
IL307625A (en) Compounds and methods for modulating pnpla3 expression
EP3931336A4 (de) Zusammensetzungen und verfahren zur behandlung von laminopathien
IL290958A (en) Methods and preparations for the modulation of cellular senescence
SG11202103316TA (en) Methods and compositions for modulation of tau proteins
EP4096675A4 (de) Zusammensetzungen und verfahren zur behandlung von long covid
EP4125978A4 (de) Zusammensetzungen und verfahren zur modulation der entzündungsreaktion
CA3263582A1 (en) COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSE
IL313220A (en) Compounds and methods for modulating APOC3 expressionCompounds and methods for modulating APOC3 expression
CA3295995A1 (en) Compositions and methods for modulating tau expression
EP4041207A4 (de) Zusammensetzungen und verfahren zum hemmen von collagenverlust
AU2020407501A1 (en) Methods and compositions for evaluating and treating fibrosis
HK40099806A (en) Compositions and methods for modulating pnpla3 expression
CA3285540A1 (en) Compositions and methods for modulating sptlc1